In this intro and overview of Skye's Anatomy of Progress video series, we highlight Skye’s positioning and progress in obesity therapeutic drug development, noting the differentiation of its allosteric modulating antibody that takes into consideration fat metabolism, safety and long-term care.

Anatomy of Progress Presentation

Hosted by Evercore healthcare equity research analysts, Skye executives join with notable obesity physicians to discuss the CB1 pathway, nimacimab’s peripheral CB1 blockade, and the broader non-incretin toolkit supporting obesity care beyond the limits of the GLP-1 era.

Skye’s poster presentation at the American Diabetes Association medical conference highlights nimacimab’s ability to achieve weight reduction and deliver comprehensive metabolic improvements including enhanced body composition, restoration of metabolic homeostasis, and improved hormonal profiles.